Exact Mass: 579.2138062
Exact Mass Matches: 579.2138062
Found 253 metabolites which its exact mass value is equals to given mass value 579.2138062,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Pelargonidin 3-rutinoside
Pelargonidin 3-rutinoside is a member of the class of compounds known as anthocyanidin-3-o-glycosides. Anthocyanidin-3-o-glycosides are phenolic compounds containing one anthocyanidin moiety which is O-glycosidically linked to a carbohydrate moiety at the C3-position. Pelargonidin 3-rutinoside is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Pelargonidin 3-rutinoside can be found in a number of food items such as gooseberry, lowbush blueberry, black chokeberry, and redcurrant, which makes pelargonidin 3-rutinoside a potential biomarker for the consumption of these food products.
Pelargonidin 3-rhamnoside 5-glucoside
Pelargonidin 3-rhamnoside 5-glucoside is found in common pea. Pelargonidin 3-rhamnoside 5-glucoside is isolated from Pisum species. Isolated from Pisum subspecies Pelargonidin 3-rhamnoside 5-glucoside is found in pulses and common pea.
Taurochenodeoxycholate-3-sulfate
C26H45NO9S2 (579.2535600000001)
Taurochenodeoxycholate-3-sulfate is a bile salt formed in the liver by conjugation of chenodeoxycholate with taurine, usually as the sodium salt. Under normal circumstances, bile acid sulfation is a minor pathway. However in the presence of cholestasis, the fraction of the bile acid pool which is sulfated increases. Sulfation of bile acids increases the aqueous solubility of the amphipathic compounds and results in more efficient renal clearance as well as in decreased reabsorption from the intestinal lumen. Bile acids are steroid acids found predominantly in the bile of mammals. The distinction between different bile acids is minute, depending only on the presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g. membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues (PMID: 11316487, 16037564, 12576301, 11907135). Taurochenodeoxycholate-3-sulfate is a bile salt formed in the liver by conjugation of chenodeoxycholate with taurine, usually as the sodium salt. Under normal circumstances, bile acid sulfation is a minor pathway. However in the presence of cholestasis, the fraction of the bile acid pool which is sulfated increases. Sulfation of bile acids increases the aqueous solubility of the amphipathic compounds and results in more efficient renal clearance as well as in decreased reabsorption from the intestinal lumen. Bile acids are steroid acids found predominantly in bile of mammals. The distinction between different bile acids is minute, depends only on presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g., membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues. (PMID: 11316487, 16037564, 12576301, 11907135) [HMDB] Taurochenodeoxycholate-3-sulfate is a bile salt found in urine[1].
Taurochenodeoxycholate-7-sulfate
C26H45NO9S2 (579.2535600000001)
Taurochenodeoxycholate-7-sulfate is a sulfated bile acid. Under normal circumstances, bile acid sulfation is a minor pathway. However in the presence of cholestasis, the fraction of the bile acid pool which is sulfated increases. Sulfation of bile acids increases the aqueous solubility of the amphipathic compounds and results in more efficient renal clearance as well as in decreased reabsorption from the intestinal lumen. Bile acids are steroid acids found predominantly in the bile of mammals. The distinction between different bile acids is minute, depending only on the presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g. membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues (PMID: 11316487, 16037564, 12576301, 11907135). Taurochenodeoxycholate-7-sulfate is a sulfated bile acid. Under normal circumstances, bile acid sulfation is a minor pathway. However in the presence of cholestasis, the fraction of the bile acid pool which is sulfated increases. Sulfation of bile acids increases the aqueous solubility of the amphipathic compounds and results in more efficient renal clearance as well as in decreased reabsorption from the intestinal lumen. Bile acids are steroid acids found predominantly in bile of mammals. The distinction between different bile acids is minute, depends only on presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g., membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues. (PMID: 11316487, 16037564, 12576301, 11907135) [HMDB] D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
Z-Gly-Gly-Arg-AMC
Rzedowskin D
Celapanigine
4-O-beta-D-glucopyranosyllinearoside
C27H33NO13 (579.1951808000001)
1beta,2beta-diacetoxy-9alpha-benzoyloxy-13-nicotinoyloxy-beta-dihydroagarofuran
4,6-Diacetoxy-5a-(benzoyloxymethyl)-5-(3-pyridylcarbonyloxy)-2H-3,9a-methano-3,4,5,5a,6,7,8,9-octahydro-2,2,9-trimethyl-1-benzooxepin
4,6-Diacetoxy-10-(benzoyloxy)-5-(3-pyridylcarbonyloxy)-2H-3,9a-methano-3,4,5,5a,6,7,8,9-octahydro-2,2,5a,9-tetramethyl-1-benzooxepin
Tauroursodeoxycholate-3-sulfate
C26H45NO9S2 (579.2535600000001)
BA-151-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-151-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-151-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-151-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
3a-Sulfooxy-12a-hydroxy-5b-cholan-24-oyl-taurine
C26H45NO9S2 (579.2535600000001)
BA-152-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-152-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-152-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-152-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-152-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
2-((4R)-4-((3R,5R,7R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-(sulfooxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid
C26H45NO9S2 (579.2535600000001)
2-((4R)-4-((3R,5R,9S,10S,12S,13R,14S,17R)-12-hydroxy-10,13-dimethyl-3-(sulfooxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid
C26H45NO9S2 (579.2535600000001)
2-((4R)-4-((3R,5R,7S,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-(sulfooxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid
C26H45NO9S2 (579.2535600000001)
Asp Glu Met Trp
Asp Glu Trp Met
Asp Met Glu Trp
Asp Met Trp Glu
Asp Pro Trp Tyr
Asp Pro Tyr Trp
Asp Trp Glu Met
Asp Trp Met Glu
Asp Trp Pro Tyr
Asp Trp Tyr Pro
Asp Tyr Pro Trp
Asp Tyr Trp Pro
Glu Asp Met Trp
Glu Asp Trp Met
Glu Met Asp Trp
Glu Met Trp Asp
Glu Trp Asp Met
Glu Trp Met Asp
Phe His Asn Tyr
Phe His Tyr Asn
Phe Met Pro Trp
Phe Met Trp Pro
Phe Asn His Tyr
Phe Asn Asn Trp
Phe Asn Trp Asn
Phe Asn Tyr His
Phe Pro Met Trp
Phe Pro Trp Met
Phe Trp Met Pro
Phe Trp Asn Asn
Phe Trp Pro Met
Phe Tyr His Asn
Phe Tyr Asn His
His Phe Asn Tyr
His Phe Tyr Asn
His His Thr Trp
His His Trp Thr
His Asn Phe Tyr
His Asn Tyr Phe
His Thr His Trp
His Thr Trp His
His Trp His Thr
His Trp Thr His
His Tyr Phe Asn
His Tyr Asn Phe
Ile Met Met Trp
Ile Met Trp Met
Ile Trp Met Met
Leu Met Met Trp
Leu Met Trp Met
Leu Trp Met Met
Met Asp Glu Trp
Met Asp Trp Glu
Met Glu Asp Trp
Met Glu Trp Asp
Met Phe Pro Trp
Met Phe Trp Pro
Met Ile Met Trp
Met Ile Trp Met
Met Leu Met Trp
Met Leu Trp Met
Met Met Ile Trp
Met Met Leu Trp
Met Met Trp Ile
Met Met Trp Leu
Met Pro Phe Trp
Met Pro Trp Phe
Met Trp Asp Glu
Met Trp Glu Asp
Met Trp Phe Pro
Met Trp Ile Met
Met Trp Leu Met
Met Trp Met Ile
Met Trp Met Leu
Met Trp Pro Phe
Asn Phe His Tyr
Asn Phe Asn Trp
Asn Phe Trp Asn
Asn Phe Tyr His
Asn His Phe Tyr
Asn His Tyr Phe
Asn Asn Phe Trp
Asn Asn Trp Phe
Asn Trp Phe Asn
Asn Trp Asn Phe
Asn Tyr Phe His
Asn Tyr His Phe
Pro Asp Trp Tyr
Pro Asp Tyr Trp
Pro Phe Met Trp
Pro Phe Trp Met
Pro Met Phe Trp
Pro Met Trp Phe
Pro Trp Asp Tyr
Pro Trp Phe Met
Pro Trp Met Phe
Pro Trp Tyr Asp
Pro Tyr Asp Trp
Pro Tyr Trp Asp
Thr His His Trp
Thr His Trp His
Thr Trp His His
Trp Asp Glu Met
Trp Asp Met Glu
Trp Asp Pro Tyr
Trp Asp Tyr Pro
Trp Glu Asp Met
Trp Glu Met Asp
Trp Phe Met Pro
Trp Phe Asn Asn
Trp Phe Pro Met
Trp His His Thr
Trp His Thr His
Trp Ile Met Met
Trp Leu Met Met
Trp Met Asp Glu
Trp Met Glu Asp
Trp Met Phe Pro
Trp Met Ile Met
Trp Met Leu Met
Trp Met Met Ile
Trp Met Met Leu
Trp Met Pro Phe
Trp Asn Phe Asn
Trp Asn Asn Phe
Trp Pro Asp Tyr
Trp Pro Phe Met
Trp Pro Met Phe
Trp Pro Tyr Asp
Trp Thr His His
Trp Tyr Asp Pro
Trp Tyr Pro Asp
Tyr Asp Pro Trp
Tyr Asp Trp Pro
Tyr Phe His Asn
Tyr Phe Asn His
Tyr His Phe Asn
Tyr His Asn Phe
Tyr Asn Phe His
Tyr Asn His Phe
Tyr Pro Asp Trp
Tyr Pro Trp Asp
Tyr Trp Asp Pro
Tyr Trp Pro Asp
Taurochenodeoxycholic acid 7-sulfate
C26H45NO9S2 (579.2535600000001)
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
2-[[(3a,5b,7b)-3-hydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]amino], Ethanesulfonic acid
C26H45NO9S2 (579.2535600000001)
2-[[(3a,5b,12a)-3-hydroxy-24-oxo-12-(sulfooxy)cholan-24-yl]amino]-Ethanesulfonic acid
C26H45NO9S2 (579.2535600000001)
2-[[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]amino]-Ethanesulfonic acid
C26H45NO9S2 (579.2535600000001)
2-[[(3a,5b,12a)-12-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]amino]-Ethanesulfonic acid
C26H45NO9S2 (579.2535600000001)
Ethanesulfonic acid, 2-[[(3a,5b,7a)-3-hydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]amino]
C26H45NO9S2 (579.2535600000001)
Pelargonidin 3-rhamnoside 5-glucoside
Taurochenodeoxycholic acid 3-sulfate
C26H45NO9S2 (579.2535600000001)
TG 100801
Droloxifene citrate
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D020011 - Protective Agents > D000975 - Antioxidants D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent
rac-8,14-Bis(tert-butyldimethylsilyloxy) Efavirenz-d4
C26H33ClD4F3NO4Si2 (579.2152715120001)
N-Acetyl-N-[1-(1,1-biphenyl-4-ylmethyl)-2-oxoazepan-3-YL]-O-phosphonotyrosinamide
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
3alpha-Sulfooxy-7alpha-hydroxy-5beta-cholan-24-oyl-taurine
C26H45NO9S2 (579.2535600000001)
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids Taurochenodeoxycholate-3-sulfate is a bile salt found in urine[1].
3alpha-Sulfooxy-12alpha-hydroxy-5beta-cholan-24-oyl-taurine
C26H45NO9S2 (579.2535600000001)
Lonijaposide H
C27H33NO13 (579.1951808000001)
A natural product found in Lonicera japonica.
N2-[1-[methyl-(phenylmethyl)amino]-3-(2-naphthalenyl)-1-oxopropan-2-yl]-N1-(2-nitrophenyl)pyrrolidine-1,2-dicarboxamide
C33H33N5O5 (579.2481568000001)
2-{benzyl[(4-methylphenyl)sulfonyl]amino}-N-(2-{[(2-furylmethyl)amino]carbonyl}phenyl)benzamide
C33H29N3O5S (579.1827824000001)
N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N,1-dimethylimidazole-4-sulfonamide
(5S,6R,9R)-N-(2-chlorophenyl)-5-methoxy-3,6,9-trimethyl-2-oxo-14-(pyridine-2-carbonylamino)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-8-carboxamide
C30H34ClN5O5 (579.2248344000001)
N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N,1-dimethylimidazole-4-sulfonamide
N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N,1-dimethylimidazole-4-sulfonamide
(3R)-2-[(R)-tert-butylsulfinyl]-4-[3-(4-cyanophenyl)phenyl]-3-(2-hydroxyethyl)-N-(pyridin-4-ylmethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
C33H33N5O3S (579.2303988000001)
2-[(2R,4aS,12aS)-8-[[(3-cyanoanilino)-oxomethyl]amino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2,3-dihydro-1H-inden-5-yl)acetamide
C33H33N5O5 (579.2481568000001)
N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N,1-dimethylimidazole-4-sulfonamide
N-[(2S,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4,4,4-trifluorobutanamide
N-[(2S,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4,4,4-trifluorobutanamide
N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N,1-dimethylimidazole-4-sulfonamide
(3S)-2-[(S)-tert-butylsulfinyl]-4-[3-(4-cyanophenyl)phenyl]-3-(2-hydroxyethyl)-N-(pyridin-4-ylmethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
C33H33N5O3S (579.2303988000001)
N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N,1-dimethylimidazole-4-sulfonamide
N-[(2S,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4,4,4-trifluorobutanamide
N-[(2R,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4,4,4-trifluorobutanamide
N-[(2R,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4,4,4-trifluorobutanamide
N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N,1-dimethylimidazole-4-sulfonamide
(3R)-2-[(R)-tert-butylsulfinyl]-4-[3-(3-cyanophenyl)phenyl]-3-(2-hydroxyethyl)-N-(pyridin-4-ylmethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
C33H33N5O3S (579.2303988000001)
(3S)-2-[(S)-tert-butylsulfinyl]-4-[3-(3-cyanophenyl)phenyl]-3-(2-hydroxyethyl)-N-(pyridin-4-ylmethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
C33H33N5O3S (579.2303988000001)
(2S,3S,4S,5R)-6-[2-[2-[7-chloro-5-(2-fluorophenyl)-2-oxo-3H-1,4-benzodiazepin-1-yl]ethyl-ethylamino]ethoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
C27H31ClFN3O8 (579.1783608000001)
2-[[(4R)-4-[(3R,5S,7R,10S,13R,17R)-3-hydroxy-10,13-dimethyl-7-sulfooxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid
C26H45NO9S2 (579.2535600000001)
2-((4R)-4-((3R,5R,7R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-(sulfooxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid
C26H45NO9S2 (579.2535600000001)
2-((4R)-4-((3R,5R,9S,10S,12S,13R,14S,17R)-12-hydroxy-10,13-dimethyl-3-(sulfooxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid
C26H45NO9S2 (579.2535600000001)
Taurochenodeoxycholate-7-sulfate
C26H45NO9S2 (579.2535600000001)
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
Pelargonidin 3-O-rutinoside
An anthocyanin cation consisting of pelargonidin having a rutinosyl [6-deoxy-alpha-L-mannosyl-(1->6)-beta-D-glucosyl] residue attached at the 3-hydroxy position.
Tauroursodeoxycholic acid 3-sulfate
C26H45NO9S2 (579.2535600000001)
methyl (4s,5s,6s)-4-{[(1r)-2-acetyl-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-5-ethenyl-6-{[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate
C28H37NO12 (579.2315642000001)
5,7-dihydroxy-2-(4-hydroxyphenyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1λ⁴-chromen-1-ylium
5,8-bis(acetyloxy)-12-(benzoyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl pyridine-3-carboxylate
methyl (4s,5r,6s)-4-{[(1r)-2-acetyl-7-hydroxy-6-methoxy-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-5-ethenyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate
C28H37NO12 (579.2315642000001)
(1s,2s,4r,5r,6r,7s,9r,12s)-7-(acetyloxy)-2,4-dihydroxy-2,6,10,10-tetramethyl-5-{[(2e)-3-phenylprop-2-enoyl]oxy}-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-12-yl pyridine-3-carboxylate
methyl 4-[(2-acetyl-7-hydroxy-6-methoxy-3,4-dihydro-1h-isoquinolin-1-yl)methyl]-5-ethenyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate
C28H37NO12 (579.2315642000001)
methyl (4s,5r,6s)-4-{[(3r)-2-acetyl-5-hydroxy-6-methoxy-3,4-dihydro-1h-isoquinolin-3-yl]methyl}-5-ethenyl-6-{[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate
C28H37NO12 (579.2315642000001)
methyl (4s,5s,6s)-4-{[(1r)-2-acetyl-7-hydroxy-6-methoxy-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-5-ethenyl-6-{[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate
C28H37NO12 (579.2315642000001)
(1r,2r,5s,6s,7r,8r,9s,12r)-5,8-bis(acetyloxy)-12-(benzoyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl pyridine-3-carboxylate
(1s,2r,4s,5r,6r,7r,9r,12r)-4,5-bis(acetyloxy)-7-(benzoyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-12-yl pyridine-3-carboxylate
n-[(2r,3r,4r,5r,6s)-3-(acetyloxy)-6-{5-ethenyl-15-hydroxy-3,17-dimethoxy-8-oxo-9-oxatetracyclo[8.8.0.0²,⁷.0¹¹,¹⁶]octadeca-1(10),2(7),3,5,11(16),12,14,17-octaen-12-yl}-5-hydroxy-2-methyloxan-4-yl]-n-methylmethanamine oxide
5,7-dihydroxy-2-(4-hydroxyphenyl)-3-{[(2s,5s)-3,4,5-trihydroxy-6-({[(2r,4s,5r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1λ⁴-chromen-1-ylium
methyl (4s,5r,6s)-4-{[(1r)-2-acetyl-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-5-ethenyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate
C28H37NO12 (579.2315642000001)
(3r,14e,16s,18r)-6-[(3-bromo-4-hydroxyphenyl)methyl]-5,11-dihydroxy-3,7,12,14,16,18-hexamethyl-1-oxa-4,7,10-triazacyclooctadeca-4,10,14-triene-2,8-dione
C27H38BrN3O6 (579.1943828000001)
methyl (4s,5r,6s)-4-{[(1s)-2-acetyl-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-5-ethenyl-6-{[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate
C28H37NO12 (579.2315642000001)
(3s,6r,12s,14e,16r,18s)-6-[(3-bromo-4-hydroxyphenyl)methyl]-5,11-dihydroxy-3,7,12,14,16,18-hexamethyl-1-oxa-4,7,10-triazacyclooctadeca-4,10,14-triene-2,8-dione
C27H38BrN3O6 (579.1943828000001)
methyl 4-[(2-acetyl-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-1-yl)methyl]-5-ethenyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate
C28H37NO12 (579.2315642000001)
2-({3-[2-(1-carboxyethyl)-1h-indol-3-yl]-1-[4-(2-methoxy-5-oxopyrrolidin-1-yl)phenoxy]-1-oxopropan-2-yl}amino)-3-methylpentanoic acid
C31H37N3O8 (579.2580522000001)
7-hydroxy-2-(4-hydroxyphenyl)-5-{[(2s,3r,4s,5s,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-{[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-1λ⁴-chromen-1-ylium
methyl 4-[(2-acetyl-5-hydroxy-6-methoxy-3,4-dihydro-1h-isoquinolin-3-yl)methyl]-5-ethenyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate
C28H37NO12 (579.2315642000001)